

Keiichiro Mori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5337869/publications.pdf>

Version: 2024-02-01

148
papers

1,811
citations

361413

20
h-index

477307

29
g-index

150
all docs

150
docs citations

150
times ranked

1616
citing authors

#	ARTICLE	IF	CITATIONS
1	Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 239-252.	3.1	12
2	Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. <i>European Urology Focus</i> , 2022, 8, 447-456.	3.1	3
3	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. <i>BJU International</i> , 2022, 129, 182-193.	2.5	16
4	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. <i>European Urology Focus</i> , 2022, 8, 710-717.	3.1	12
5	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 761-768.	3.1	10
6	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	4.2	6
7	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. <i>European Urology Focus</i> , 2022, 8, 752-760.	3.1	8
8	Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers. <i>World Journal of Urology</i> , 2022, 40, 1317-1323.	2.2	8
9	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	2
10	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. <i>European Urology Oncology</i> , 2022, 5, 138-145.	5.4	6
11	Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. <i>BJU International</i> , 2022, 129, 423-433.	2.5	37
12	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1072-1089.	3.1	14
13	Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2022, 40, 907-914.	2.2	19
14	Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2022, 82, 3-12.	2.3	9
15	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	2.7	6
16	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. <i>Journal of Endourology</i> , 2022, 36, 535-547.	2.1	11
17	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 95.e1-95.e6.	1.9	20
18	Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2022, 32, 61-68.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. <i>World Journal of Urology</i> , 2022, 40, 747-754.	2.2	4
20	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 106.e11-106.e19.	1.6	14
21	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 59-71.	2.2	19
22	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 227-236.	1.9	3
23	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	2.5	2
24	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103570.	4.4	11
25	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	8
26	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	3.1	3
27	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. <i>European Urology Oncology</i> , 2022, 5, 120-124.	5.4	6
28	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. <i>Scandinavian Journal of Urology</i> , 2022, 56, 85-93.	1.0	3
29	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2022, 20, 71-80.	1.5	2
30	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. <i>World Journal of Urology</i> , 2022, , 1.	2.2	0
31	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	1.5	6
32	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urologyâ€”Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	3.1	7
33	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	3.1	10
34	Prognostic impact of insulinâ€”like growth factorâ€”1 and its binding proteins, insulinâ€”like growth factorâ€”1 binding proteinâ€”2 and â€”3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , .	1.0	3
35	Comparative Outcomes of Primary Versus Recurrent High-risk Nonâ€”muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. <i>European Urology Open Science</i> , 2022, 39, 14-21.	0.4	7
36	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720.	3.8	13

#	ARTICLE	IF	CITATIONS
37	The placebo and nocebo effects in functional urology. <i>Nature Reviews Urology</i> , 2022, 19, 171-189.	3.8	5
38	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. <i>Journal of Robotic Surgery</i> , 2022, 16, 1233-1247.	1.8	6
39	ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
40	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	1.9	15
41	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725.	2.0	10
42	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 908-917.	1.0	2
43	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
44	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	2.2	20
45	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021, 7, 1143-1156.	3.1	6
46	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 143-152.	2.5	5
47	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 265-273.	4.2	44
48	Primary Ta high grade bladder tumors: Determination of the risk of progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 132.e7-132.e11.	1.6	9
49	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e5-235.e14.	1.6	8
50	Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses. <i>BJU International</i> , 2021, 128, 3-11.	2.5	25
51	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 79, 783-792.	1.9	46
52	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 59-66.	1.5	12
53	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 617-625.	2.5	13
54	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1149-1157.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 315-324.	2.0	5
56	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3345-3352.	2.2	18
57	The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 205, 60-67.	0.4	36
58	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, S33-S44.	1.3	1
59	Prognostic role of the systemic immune-inflammatory index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2641-2650.	4.2	21
60	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	1.4	5
61	Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. <i>World Journal of Urology</i> , 2021, 39, 2977-2985.	2.2	6
62	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. <i>Current Opinion in Urology</i> , 2021, 31, 276-284.	1.8	7
63	Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 79, 430-431.	1.9	0
64	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 180-190.	1.6	10
65	A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. <i>Minerva Urology and Nephrology</i> , 2021, 73, 42-49.	2.5	4
66	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 755-765.	5.4	100
67	Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Journal of Urology</i> , 2021, 205, 1018-1030.	0.4	27
68	Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.10.006 . Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?. <i>European Urology</i> , 2021, 79, e113-e114.	1.9	0
69	Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 976-985.	2.0	4
70	Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 332-339.	1.8	9
71	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 80, 549-563.	1.9	53
72	Association between male infertility and prostate cancer: a systematic review and meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 346-353.	1.8	3

#	ARTICLE	IF	CITATIONS
73	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 4085-4099.	2.2	9
74	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. <i>BJU International</i> , 2021, 128, 280-289.	2.5	17
75	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. <i>Prostate</i> , 2021, 81, 765-771.	2.3	4
76	Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. <i>Current Opinion in Urology</i> , 2021, 31, 297-303.	1.8	8
77	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. <i>World Journal of Urology</i> , 2021, 39, 3771-3779.	2.2	10
78	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1172-1178.	1.0	7
79	Presence of biopsy Gleason pattern 5+3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. <i>Prostate</i> , 2021, 81, 778-784.	2.3	2
80	Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2. <i>Current Opinion in Urology</i> , 2021, 31, 304-314.	1.8	11
81	ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?. <i>Annals of Surgical Oncology</i> , 2021, 28, 9188-9189.	1.5	0
82	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 9179-9187.	1.5	3
83	Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 205, 1559-1568.	0.4	2
84	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1587-1599.	2.2	16
85	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.4	5
86	Impact of systemic immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e19-785.e27.	1.6	14
87	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4355-4361.	2.2	18
88	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	2.2	3
89	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 806-815.	1.6	7
90	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. <i>Current Oncology</i> , 2021, 28, 2881-2892.	2.2	16

#	ARTICLE	IF	CITATIONS
91	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 151, 35-48.	2.8	24
92	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 409-421.	1.6	17
93	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 764-773.	1.6	14
94	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. <i>Immunotherapy</i> , 2021, 13, 917-929.	2.0	1
95	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 471-479.	1.6	7
96	The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4197.	2.4	16
97	The Prognostic Association of Prostate MRI PI-RADS [®] v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 206, 507-516.	0.4	22
98	Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2021;79:783-92. <i>European Urology</i> , 2021, 80, e145-e146.	1.9	0
99	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	7.7	13
100	Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. <i>Seminars in Oncology</i> , 2021, 48, 181-192.	2.2	2
101	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. <i>World Journal of Urology</i> , 2021, , 1.	2.2	3
102	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	5.4	40
103	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1231.	2.5	5
104	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. <i>Minerva Urology and Nephrology</i> , 2021, 73, 610-615.	2.5	6
105	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. <i>Central European Journal of Urology</i> , 2021, 74, 484-490.	0.3	2
106	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	8
107	The Impact of Primary Tumor Location on Long-Term Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1363.	2.5	1
108	Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naïve Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e46-e54.	1.9	9

#	ARTICLE	IF	CITATIONS
109	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 479-485.	2.2	1
110	Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e402-e409.	1.9	15
111	En bloc resection for nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 41-47.	1.8	40
112	Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 247-257.	2.2	25
113	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 936.e7-936.e14.	1.6	3
114	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 701-710.	1.8	6
115	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	2.2	6
116	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1881-1891.	2.2	8
117	The significance of De Ritis ratio in patients with radiation-recurrent prostate cancer undergoing salvage radical prostatectomy. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 213-218.	1.5	7
118	Smoking and bladder cancer: review of the recent literature. <i>Current Opinion in Urology</i> , 2020, 30, 720-725.	1.8	17
119	Volume outcome relationship in penile cancer: a systematic review. <i>Current Opinion in Urology</i> , 2020, 30, 696-700.	1.8	10
120	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1892-1900.	2.2	45
121	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). <i>World Journal of Urology</i> , 2020, 39, 1961-1968.	2.2	10
122	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1459-1474.	2.2	25
123	The clinical pharmacology of the medical treatment for overactive bladder in adults. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 707-720.	3.1	8
124	Management of de-novo urothelial carcinoma in transplanted patients. <i>Current Opinion in Urology</i> , 2020, 30, 467-474.	1.8	7
125	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 539-548.	3.9	27
126	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 601.e17-601.e24.	1.6	12

#	ARTICLE	IF	CITATIONS
127	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1037-1054.	2.2	31
128	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 774-782.	1.6	26
129	Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 315-333.	1.6	32
130	Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e517-e522.	1.9	11
131	Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 77, 758-759.	1.9	0
132	Catalog of exogenous risk factors for bladder carcinogenesis. <i>Current Opinion in Urology</i> , 2020, 30, 449-456.	1.8	14
133	Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1075-1084.	0.4	30
134	Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 204, 58-62.	0.4	19
135	The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 204, 909-917.	0.4	21
136	A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Journal of Urology</i> , 2020, 204, 1129-1140.	0.4	41
137	Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 531-542.	3.9	9
138	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 685.e17-685.e25.	1.6	2
139	Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?. <i>Current Opinion in Urology</i> , 2020, 30, 584-593.	1.8	5
140	No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1604-1610.	2.3	1
141	Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 980-984.	1.0	9
142	Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 409-418.	1.9	24
143	Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis-Targeted Agents. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 223-230.	1.9	13
144	The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 315-315.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 766-772.	2.3	9
146	Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1144-1150.	2.3	29
147	Does Gleason pattern 5 influence the efficacy of enzalutamide against castration-resistant prostate cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, e598-e598.	1.6	0
148	Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. <i>World Journal of Urology</i> , 0, , .	2.2	3